Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
Iulian Alecu, Tsveta Milenkova, Simon R Turner Research and Development, AstraZeneca UK Limited, Cambridge, UKThe tolerability profile of PARP inhibitors often includes hematologic toxicities, and the characterization of these adverse events is important to allow effective management by clinicians....
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Kitap |
| Baskı/Yayın Bilgisi: |
Dove Medical Press,
2018-02-01T00:00:00Z.
|
| Konular: | |
| Online Erişim: | Connect to this object online. |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Internet
Connect to this object online.3rd Floor Main Library
| Yer Numarası: |
A1234.567 |
|---|---|
| Kopya Bilgisi 1 | Kütüphanede |